Qurish K. Mohemmad
Ariadne Diagnostics (United States)(US)
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Eosinophilic Disorders and Syndromes, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase(2016)396 cited
- → Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant(2010)358 cited
- → The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2016)321 cited
- → Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models(2012)317 cited
- → Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies(2011)151 cited
- → Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen(2011)131 cited
- → Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models(2013)57 cited
- → Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066)(2010)50 cited
- → Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)(2010)27 cited
- Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)(2009)